Navigation Links
Stereotaxis and Siemens Promote Integrated Odyssey(TM) Solutions
Date:5/12/2010

ST. LOUIS, May 12 /PRNewswire-FirstCall/ -- At the Heart Rhythm Society's 31st Annual Scientific Sessions, Stereotaxis, Inc. (Nasdaq: STXS) will promote its Odyssey Enterprise Solution with a live network connection between the Stereotaxis and Siemens Healthcare exhibits.  The demonstration will be remotely powered through the Stereotaxis Odyssey Enterprise Cinema platform connected to a customer viewing station in the Siemens booth to demonstrate the capability of remote viewing, recording and collaboration in Siemens large display for Artis zee® labs.  Attendees will experience the innovative features of Odyssey Enterprise Cinema and Network Connect in combination with the Siemens consolidated display.  The exhibits will be open from May 13 to 15 at the Colorado Convention Center in Denver, Colorado, with each company offering its components for sale at HRS.

"Siemens remains focused on delivering innovative solutions to our cardiology customers, such as the ability to acquire three-dimensional images of the heart's structures utilizing syngo® DynaCT Cardiac and to distribute and display the information to the clinical team to support decision-making," said Claus Grill, vice president, Cardiac, Interventional/Neuro, and X-ray Systems, Siemens Healthcare. "Odyssey Enterprise Cinema and Network Connect is clearly aligned with this initiative by delivering synchronized data from Siemens labs throughout hospital networks and around the world."

"The integration of state-of-the-art Siemens labs with Odyssey Enterprise Solutions provides a great opportunity for Stereotaxis," said Michael P. Kaminski, Stereotaxis President and CEO. "The combination of the large display solution from Siemens with Odyssey offers a powerful combination of products that will deliver real value to our joint customers."  

About Odyssey   www.OdysseyExperience.com

The Odyssey portfolio of products provides an innovative enterprise solution for integrating, recording, and networking interventional lab information around the world.  Odyssey Vision standardizes data integration for magnetic and standard interventional labs by enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems.  Odyssey Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed.  Through its proprietary data compression technology, Cinema enables sharing of live and recorded procedure data via a laptop anywhere over a secure high speed Internet connection.  Hospitals can also share procedures with other institutions using Odyssey Network Connect providing a global forum for defining clinical best practices across a broad spectrum of medical procedures.

About Stereotaxis   www.Stereotaxis.com

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. Stereotaxis' Odyssey solutions integrate and manage information from disparate information sources, eliminating the challenge of interacting simultaneously with many separate diagnostic systems, driving optimized workflow and improved productivity. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions.  Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements.  Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission.  By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.  There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control.  In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis Announces Vdrive(TM), a New Technology for Remote Navigation of Diagnostic Devices
2. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
3. Stereotaxis Installs First System in Taiwan
4. Stereotaxis System Procedure Featured on NBCs The TODAY Show
5. Stereotaxis is Notified of the FDA Approval of an Additional Magnetic Irrigated Catheter
6. Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter
7. Stereotaxis Announces Underwriters Exercise of Over-Allotment Option
8. Stereotaxis Announces Pricing of $26 Million Common Stock Offering
9. Stereotaxis Announces Public Offering of Common Stock
10. Stereotaxis Receives Commitment to Increase and Extend Its Credit Facility With Silicon Valley Bank
11. Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart Rhythm 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. ... and markets innovative proprietary products for the urology market, ... fiscal year ended December 31, 2016 before the market ... The Company will host a conference call and webcast ... Thursday, March 9, 2017 at 11:00 a.m. Eastern Time ...
(Date:2/23/2017)... Feb 23, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Menopause market? ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... - 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price ... in the global Fibromyalgia market. The research answers the ... marketed for Fibromyalgia and their clinical attributes? How are they positioned ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... , media relations, content marketing, social media management, corporate communications, SEO and cause ... the state and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus ...
(Date:2/23/2017)... Colorado (PRWEB) , ... February 23, 2017 , ... ... Magazine, an exciting, new, interactive publication where generations converge and explore the world ... expand their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... new partnership with the Rhode Island Consortium for Autism Research and Treatment (RI-CART) ... for children with autism spectrum disorder (ASD) to see films in an environment ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/22/2017)... York (PRWEB) , ... February 22, 2017 , ... ... entrance and lobby of a new healthcare contact center in Georgia, PENETRON Specialty ... One of the nation’s largest healthcare systems recently invested $51 million to purchase ...
Breaking Medicine News(10 mins):